Generate Biomedicines (GENB) logo

Generate Biomedicines' IPO

Generate Biomedicines · Filed Feb 4 · Nasdaq · Form S-1

Listed Feb 27, 2026 at $16 on Nasdaq as GENB. Today 40% below its $16 offer price; its first day closed -20.9%.

Offer price: $16, a share
Shares: 25M, offered
Ticker: GENB, Nasdaq

From its final prospectus (424B4) on SEC EDGAR.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

See GENB ranked, liveSee GENB ranked, liveSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What does Generate Biomedicines do?

Generate Biomedicines' facts, each with its source
FactGenerate
Biomedicines
What it does“We are a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development.”From its final prospectus (424B4) of Feb 27, 2026
Founded2018From its final prospectus (424B4) of Feb 27, 2026
HeadquartersSomerville, MassachusettsFrom its final prospectus (424B4) of Feb 27, 2026
Employees312 full-time, as of December 31, 2025From its final prospectus (424B4) of Feb 27, 2026
Websitegeneratebiomedicines.comFrom its final prospectus (424B4) of Feb 27, 2026

What is the offering?

Each figure names the filing it is from and that filing's date.

Generate Biomedicines' facts, each with its source
FactGenerate
Biomedicines
Shares offered25,000,000From the final prospectus (424B4) filed Feb 27, 2026
Offer price$16 a shareFrom the final prospectus (424B4) filed Feb 27, 2026
Raised at that price$400 millionFrom the final prospectus (424B4) filed Feb 27, 2026
Underwriters' discount$26 millionFrom the final prospectus (424B4) filed Feb 27, 2026
Underwriters' option3,750,000 more sharesFrom the final prospectus (424B4) filed Feb 27, 2026
UnderwritersGoldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities, and CantorFrom the final prospectus (424B4) filed Feb 27, 2026, as its cover names them
ExchangeNasdaq Global Select Market, as GENBFrom the final prospectus (424B4) filed Feb 27, 2026

What the filing says about its money

Generate Biomedicines' facts, each with its source
FactGenerate
Biomedicines
Collaboration revenue$31.9 million, year to December 31, 2025From its final prospectus (424B4) of Feb 27, 2026, its summary financial data
Net loss$223 million, year to December 31, 2025From its final prospectus (424B4) of Feb 27, 2026, its summary financial data
Cash$222 million, as of December 31, 2025From its final prospectus (424B4) of Feb 27, 2026: cash, cash equivalents and marketable securities
Last preferred stockSeries C preferredFrom its final prospectus (424B4) of Feb 27, 2026

What risks does Generate Biomedicines name first?

  1. “We are a clinical-stage biotechnology company with a limited operating history and no products approved by regulators for commercial sale, which may make it difficult to evaluate our current and future business prospects.”
  2. “Even if this offering is completed, we will require substantial additional capital to finance our operations in the future.”
  3. “Our approach to the engineering and development of our programs is unproven, and we may not be successful in our efforts to identify and develop any programs and product candidates of commercial value by leveraging our Generate Platform.”

The first three of the risks its prospectus summary lists, in the company's words. The rest, and each in full, are in the filing. Read the filing.

Dates so far

Generate Biomedicines' IPO dates, each with its source
WhatDay
Registration filedForm S-1, SEC EDGARFeb 4, 2026
Exchange registration filedexchange registration (Form 8-A), SEC EDGARFeb 24, 2026
Declared effective by the SECSEC notice of effectiveness, SEC EDGARFeb 26, 2026
Pricedfinal prospectus (424B4), filed Feb 27, SEC EDGARFeb 26, 2026
First tradeMassive's IPO calendarFeb 27, 2026
Lock-up endsfinal prospectus, SEC EDGAR: “180 days after the date of this prospectus”Aug 25, 2026

How did its first days trade?

From its daily bars, each close against its $16 offer price.

Generate Biomedicines' first sessions
DayOpenCloseFrom the
offer
Feb 27$15$12.65-20.9%
Mar 2$12.01$12.17-23.9%
Mar 3$12.36$11.93-25.4%
Mar 4$12.40$11.58-27.6%
Mar 5$11.34$12.45-22.2%

What is Generate Biomedicines' Quality Score?

0

Poor

186 trading days so far; 1 of the 14 checks wait for more history.

GENB's page, with every reason behind its score

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

The other IPOs expected

The other IPOs expected or in registration
CompanyPrice

Generate Biomedicines IPO questions

When is Generate Biomedicines' IPO?

Listed Feb 27, 2026 at $16 on Nasdaq as GENB.

What is Generate Biomedicines' IPO price?

Generate Biomedicines' IPO priced at $16 a share, per its final prospectus of Feb 27, 2026.

How many shares is Generate Biomedicines selling?

25,000,000 shares, and the underwriters may buy 3,750,000 more, per its final prospectus (424B4).

Who are the underwriters?

Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities, and Cantor, as the prospectus's cover names them.

When does the lock-up end?

Generate Biomedicines' IPO lock-⁠up ends Aug 25, 2026. Its final prospectus says: “180 days after the date of this prospectus.”

Does Breakaway rate Generate Biomedicines?

Generate Biomedicines has a Quality Score of -1 today. The score counts the 14 chart checks and the company's filings; a check that needs more history than a new stock has waits for it.

Can Breakaway say where Generate Biomedicines' price will go?

No. Breakaway does not say where a price will go. Every figure here is from the company's SEC filings, linked on each line.

Where every figure comes from: how the IPO pages are made.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Every new listing, ranked live.

Each stock that listed in the last 90 days, with its Quality Score from its second day of trading, its insider filings, and its lock-up date, and an optional alert the day a company you follow lists.

See all 12 new listings rankedSee all 12 new listings rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Sources: Generate Biomedicines, Inc.'s final prospectus (424B4) of Feb 27, 2026; the prices, the stock's daily bars, 15 minutes behind.

Not advice. Figures from each company's SEC filings, linked on each line. Breakaway is not an underwriter, broker, or adviser, and does not say where a price will go.

Scores as of 8:50 PM ET, 15 minutes behind.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.